論文

国際誌
2019年12月

Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.

Leukemia & lymphoma
  • Satoshi Dote
  • ,
  • Kaori Ito
  • ,
  • Shoji Itakura
  • ,
  • Takeo Yasu
  • ,
  • Daiki Hira
  • ,
  • Satoshi Noda
  • ,
  • Shigeki Yamada
  • ,
  • Yuka Kobayashi
  • ,
  • Tomohiro Terada

60
12
開始ページ
2975
終了ページ
2981
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1080/10428194.2019.1608531

This retrospective cohort study was conducted to investigate the association between prior bortezomib (BOR) therapy and lenalidomide (LEN)-induced rash in multiple myeloma (MM) patients. Eligible MM patients initially treated with LEN were divided into two propensity score-matched cohorts according to the presence or absence of prior BOR therapy. The primary endpoint of the study was rash incidence. We evaluated 144 patients and each cohort contained 43 patients after matching propensity-score. Rash incidence significantly decreased in patients with prior BOR therapy than in those without (30% vs. 53%, p < .05). Moreover, patients with rash showed a significantly higher incidence of eosinophilia within 1 month after LEN initiation than those without rash. Our findings indicate that prior BOR therapy may reduce the incidence of LEN-induced rash, which may be characterized by eosinophilia. Accordingly, in patients who discontinued LEN therapy due to rash, LEN re-treatment may be successful after BOR therapy.

リンク情報
DOI
https://doi.org/10.1080/10428194.2019.1608531
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31046497
ID情報
  • DOI : 10.1080/10428194.2019.1608531
  • PubMed ID : 31046497

エクスポート
BibTeX RIS